Lupus Science & Medicine

Article	Citations
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	51
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	51
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	50
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	46
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	42
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	39
Towards a minimal core dataset for systemic lupus erythematosus studies	38
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	37
Genetic load in incomplete lupus erythematosus	34
Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality	30
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort	30
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	26
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus	25
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	25
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	24
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	24
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	23
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	22
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	22
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain	22
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus	21
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	21
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial	21
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	20

Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	20
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	19
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	19
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated	19
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	18
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	18
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	17
Frequency-dependent and temporal variability of low-frequency fluctuations in patients with primary Sjögren’s syndrome	17
Cortical changes in women with systemic lupus erythematosus with mild cognitive impairment: a voxel-based morphometry and surface-based morphometry study	17
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts	17
Prevalence and determinants of vertebral fractures in a SLE cohort	17
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis	17
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus	16
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort	16
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden	16
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	16
Function of follicular helper 17 T cells in driving B cells for anti-DNA autoantibody production in patients with SLE	15
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort	15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond	15
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE	15
Prevalence and predictive factors associated with sustained remission in SLE: a systematic review	15
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE	15
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	15
Dyspigmentation and scarring in cutaneous lupus erythematosus	15
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus	14
Canadian patient experiences of lupus nephritis: a qualitative analysis	14
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups	14
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus	14
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis	14
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	13
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway	13
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus	13
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis	13
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study	13
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes	12
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas	12
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	12
Discrepant anti-dsDNA testing between EliA and Crithidia in ANA negative samples: just a false positive?	12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE	12
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus	12
Lupus spectrum ambiguity has long-term negative implications for patients	12
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE	12
Potential causal effect of SLE on osteoporosis, and the mediation effect: a Mendelian randomisation study	11
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA	11
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	11
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework	11
Association between disease duration and comorbidity burden in systemic lupus erythematosus: a multicentre study from Pakistan	11
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a	11
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	11
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	11

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	10
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus	10
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	10
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	10
Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis	10
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	10
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C3	10
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	10
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease	10
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	10
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	10
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	9
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	9
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	9
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	9
Validation of eight endotypes of lupus based on whole-blood RNA profiles	9
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	9
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	9
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis	9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	9
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	8
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	8
Proteins upregulated in thrombotic antiphospholipid syndrome linked to platelet function in contrast with non-antiphospholipid-related thrombosis: insights from two systematic reviews	8
Systemic lupus erythematosus comorbid with chronic spontaneous urticaria: a multicentre retrospective study	8
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	8
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort	8
Dietary Intervention for Systemic Lupus Erythematosus patients based on HLA-DQ2 and DQ8 genotyping (DISH): a protocol for a randomised controlled study	8
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week p	8
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort	7
Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus	7
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database	7
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	7
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus	7
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	7
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	7
HDAC3 knockdown inhibits ferroptosis via upregulating Nrf2 to alleviate renal interstitial fibrosis in lupus nephritis	7
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE	7
Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice	6
Predictors of patient-reported outcomes phenotypes in SLE during remission: a cluster analysis approach	6
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA	6
Phenotypically driven subgroups of primary antiphospholipid syndrome-associated thrombocytopenia display distinct outcomes: a prospective cohort study with cluster analysis	6
Prevalence of major adverse cardiovascular events among Saudi patients with systemic lupus erythematosus compared with the general population: updates from the national SLE and PURE cohorts	6
Assessing grey matter structural alterations in systemic lupus erythematosus using synthetic MRI	6
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas	6
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	6
Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis	6
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis	6
Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China	6
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus	6
Does social support reduce bodily pain among African American women with SLE? Findings from a randomised controlled trial	6
Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus	6
Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life	6
NLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs	6
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data	6
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients	6
Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE	6
Effects of dual-task exercises on cognitive status, disease activity and quality of life in childhood-onset systemic lupus erythematosus	6
Association of phenotypic frailty and hand grip strength with telomere length in SLE	6
Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse	6
Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets	6
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus	6
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study	6
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen	6
Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database	6
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis	6
Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage	5
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis	5
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors	5
p16Ink4a, a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus	5
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	5
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus	5
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology	5
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells	5
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis	5
Epidemiology of patients with moderate-to-severe SLE in Sweden	5

Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus	5
Systemic lupus in the era of machine learning medicine	5
Association of modified primary efficacy response rates at 1 year and outcomes in a cohort of lupus nephritis in Jamaica	5
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study	5
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus	5
Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study	5
Burden of herpes zoster among patients with systemic lupus erythematosus in the USA	5
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	4
Correction: Differences in reproductive health discussions in an urban hispanic population with SLE: lessons from the field	4
5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE	4
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol	4
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis	4
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype	4
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	4
Abnormally high expression of D1-like dopamine receptors on lupus CD4+ T cells promotes Tfh cell differentiation	4
Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity	4
Myocardial Performance Index to assess cardiac function in autoimmune connective tissue disease: a systematic review and meta-analysis	4
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus	4
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	4
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Stu	4
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	4
Immune-mediated thrombotic thrombocytopenic purpura with systemic lupus erythematosus: clinical features and outcome	4
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study	4
Next generation sequencing analysis reveals complex genetic architecture of childhood-onset systemic lupus erythematosus	4
Failing maternal–fetal tolerance in SLE (FaMaLE): a prospective cohort study for finding the molecular mechanisms behind pregnancy complications	4
Alignment of contraception use with the ACR reproductive health guidelines in women with systemic lupus erythematosus within the RISE registry	3
Using photovoice to investigate patient experiences of lupus nephritis in Canada	3
Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis	3
Multidisciplinary re-evaluation of neuropsychiatric events to confirm the neuropsychiatric lupus diagnosis at an Indonesian tertiary hospital	3
Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study	3
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus	3
Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE	3
Detection rate, demographic associations and clinical implications of anti-C1q antibody elevations across diverse disease states	3
Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients	3
Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy	3
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS	3
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus	3
Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data	3
Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage	3
Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity	3
Comparison of TLR4, NF-κB and IRF3 expression in kidney tissue between lupus nephritis (LN) and systemic lupus erythematosus (SLE): a pristane-induced lupus mice model study	3
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	3
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial	3
Association of patient copayment and medication adherence in systemic lupus erythematosus	3
Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study	3
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus	3
Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis	3
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis	3
Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus	3
Immune gene expression and functional networks in distinct lupus nephritis classes	3
Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study	3
Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries	3
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective	3
Rural–urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA	3
Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations	3
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA	3
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis	3
Epidemiology of SLE in Italy: an observational study using a primary care database	3
Development and validation of nomograms for predicting activity index and tubulointerstitial lesions in lupus nephritis: a multicentre study	3
Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials	3
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials	3
Complete blood count-derived biomarkers as indicators of systemic lupus erythematosus activity: a cross-sectional comparative study	3
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis	3
Prevalence and incidence of systemic lupus erythematosus in Thailand based on national health data	3
Medication-related hospitalisations in patients with SLE	3